Hikma Pharmaceuticals (LON:HIK) Shares Up 7.6% – Should You Buy?

Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) shot up 7.6% during trading on Tuesday . The stock traded as high as GBX 1,670 and last traded at GBX 1,661. Approximately 1,945,266 shares were traded during trading, a decline of 67% from the average daily volume of 5,900,212 shares. The stock had previously closed at GBX 1,544.

Analysts Set New Price Targets

A number of research firms recently weighed in on HIK. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 195 target price on shares of Hikma Pharmaceuticals in a report on Monday, June 22nd. Berenberg Bank reissued a “buy” rating and issued a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, April 28th. Finally, Jefferies Financial Group raised their target price on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a report on Tuesday, May 5th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of GBX 1,687.

Get Hikma Pharmaceuticals alerts:

Get Our Latest Research Report on Hikma Pharmaceuticals

Hikma Pharmaceuticals Trading Up 7.6%

The company has a debt-to-equity ratio of 61.84, a current ratio of 1.82 and a quick ratio of 1.27. The firm’s fifty day moving average is GBX 1,462.26 and its two-hundred day moving average is GBX 1,445.59. The firm has a market capitalization of £3.53 billion, a PE ratio of 9.18, a PEG ratio of 2.38 and a beta of 0.65.

Hikma Pharmaceuticals Company Profile

(Get Free Report)

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

Featured Stories

• Five stocks we like better than Hikma Pharmaceuticals
• SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
• The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
• Palantir’s CEO Just Called Out OpenAI and Anthropic
• Abivax: Wall Street Catches Up to the Data

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.